Skip to main content
VISEN Pharmaceuticals logo

VISEN Pharmaceuticals — Investor Relations & Filings

Ticker · 2561 ISIN · KYG9363A1003 LEI · 254900OJ8HIP6GRV1044 HKEX Manufacturing
Open in API
Filings indexed 76 across all filing types
Latest filing 2026-06-08 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 2561

About VISEN Pharmaceuticals

http://www.visenpharma.com

VISEN Pharmaceuticals is an innovative biopharmaceutical company focused on the development and commercialization of paradigm-shifting therapies for endocrine diseases. The company is committed to addressing unmet medical needs within the Greater China market by providing innovative treatments and compassionate patient care. VISEN's core strategy involves leveraging advanced drug delivery platforms, which utilize prodrugs connected to carrier molecules via a linker structure. This technology enables the controlled, slow release of the unmodified prototype drug, ensuring sustained therapeutic action while the linker and carrier are safely excreted. VISEN serves as a key strategic partner for global biopharma companies seeking to commercialize high-quality endocrine assets in the region.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is a Hong Kong Stock Exchange ‘Next Day Disclosure Return’ (Form FF305) detailing changes in issued/treasury shares and on‐market share repurchases, including dates, number of shares, prices, and confirmations under listing rules. It is not an AGM, earnings, or management report but a formal regulatory report on the company’s own share transactions. This fits the “Transaction in Own Shares” category (POS).
2026-06-08 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) detailing changes in issued shares, treasury shares, and a share repurchase report under Main Board Rule 13.25A and 10.06. It provides transaction details of the company buying back its own shares. This fits the “Transaction in Own Shares” category (POS).
2026-06-05 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) detailing changes in issued shares and treasury shares, specifically a share repurchase (buyback) and associated treasury holdings. It is a regulatory notice of a transaction in the company’s own shares, not a full financial report or annual filing. This aligns exactly with the “Transaction in Own Shares” category (POS).
2026-06-04 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is a Hong Kong “Next Day Disclosure Return” (Form FF305) submitted under the Main Board/GEM Listing Rules. It details changes in issued and treasury shares, including a share repurchase on‐market, closing balances, and confirmations required by the listing rules. It is a report of the company buying back its own shares, not an earnings release or annual report. Therefore it falls under “Transaction in Own Shares” (POS).
2026-06-03 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 85% confidence The document is a Next Day Disclosure Return (FF305) filed under Hong Kong Stock Exchange rules, detailing changes in issued shares, treasury shares, and share repurchases (on-market buybacks) for VISEN Pharmaceuticals. It contains specific transaction data on repurchase volumes, prices, and confirmation of compliance with listing rules. This is not an earnings release, annual report, or general regulatory announcement, but a report of the company buying back its own shares. Therefore, it falls under Transaction in Own Shares (Code: POS).
2026-06-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
Share Issue/Capital Change Classification · 87% confidence The document is an HKEX FF301 Monthly Return detailing movements in authorised/registered share capital, issued shares, treasury shares, repurchases and confirmations under the Listing Rules (Chapter 19B). It is a regulatory disclosure of share capital changes rather than a full financial report or other meeting material. Therefore it is a capital change announcement.
2026-06-02 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.